Showing 2801-2810 of 3039 results for "".
- Nicox Receives Formulation Patent Extending NCX 470 US Patent Coverage to 2039https://modernod.com/news/nicox-receives-formulation-patent-extending-ncx-470-us-patent-coverage-to-2039/2477270/Nicox has received approval from the U.S. Patent and Trademark Office of a formulation patent for NCX 470, extending the U.S. patent coverage to 2039. NCX 470, a novel second gener
- USRetina Announces RetinaOS To Help Practices Better Understand and Manage Business Efficientlyhttps://modernod.com/news/usretina-announces-retinaos-to-help-retina-practices-understand-and-manage-the-business-efficiently/2477257/USRetina announced new technology offerings it says will drive more value for retina practices. USRetina’s new cloud-based platform, known as RetinaOS, includes RetinaInventory, an inventory management and practice data consolidation solution, and RetinaPurchasing, a group purchasing portal that
- Bausch + Lomb Secures Additional Approvals of Vyzulta in Hong Kong and Argentinahttps://modernod.com/news/bausch-lomb-secures-additional-approvals-of-vyzulta-in-hong-kong-and-argentina/2477234/Nicox announced that its partner, Bausch + Lomb, has received approval for Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% in Hong Kong and Argentina. With these approvals, Vyzulta is now approved for commercialization in a total of five countries and territories. Vyzulta is indi
- Neuroptika Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Dry Eye Diseasehttps://modernod.com/news/neuroptika-announces-enrollment-of-first-patient-in-phase-2-clinical-trial-for-dry-eye-disease/2477235/Neuroptika announced that the first patient was enrolled in a phase 2 clinical trial of NRO-1 for the treatment of dry eye disease. NRO-1 is a novel therapeutic with the potential to protect and regenerate corneal nerves in ophthalmic diseases. “Existing treatments for dry eye diseas
- Analysis: FDA’s Efforts to Speed Drug Approval May Have Led to Less Rigorous Clinical Outcome Requirementshttps://modernod.com/news/analysis-fdas-efforts-to-speed-drug-approval-may-have-led-to-less-rigorous-clinical-outcome-requirements/2477231/An analysis published in JAMA suggests that efforts by the FDA to speed the development and approval of drugs may have led to a reduction in the amount of evidence available at the time of authorization by the agency and an increase in more surrogate measures. However, the authors noted
- Improved Reimbursement for Endoscopic Cyclophotocoagulation (ECP) when Combined with Cataract Surgeryhttps://modernod.com/news/improved-reimbursement-for-endoscopic-cyclophotocoagulation-ecp-when-combined-with-cataract-surgery/2477219/Beaver-Visitec International (BVI) expressed support for two new CPT codes and improved reimbursement for ECP when combined with cataract surgery. Up to 1 in 5 patients [1] undergoing cataract extraction suffers from glaucoma, and ECP remains an important option for ophtha
- Eyevensys Closes $30M Series B Financinghttps://modernod.com/news/eyevensys-closes-30m-series-b-financing/2477210/Eyevensys announced that it has completed a $30 million Series B financing. The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic noninfectious uveitis (NIU), including the launch of its Electro Study. This phase 2 trial, to
- Oxurion Reports Positive Topline Data From Phase 1 Study of THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-nv-reports-positive-topline-data-from-phase-1-study-evaluating-thr-687-for-treatment-of-dme/2477208/Oxurion has reported positive topline data from a phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist for the treatment of diabetic macular edema (DME). The phase 1, open-label, multicenter, single dose escalation study evaluated the safety of a single intravitreal inj
- Market Scope: Ophthalmic Deals Surge in 2018-2019; Most Transactions Involve New Ventureshttps://modernod.com/news/market-scope-ophthalmic-deals-surge-in-2018-2019-most-transactions-involve-new-ventures/2477195/Ophthalmic deals garnered over $9 billion from January 2018 through October 2019, driven largely by dry eye and retina related fundraising. Over 100 transactions occurred during this period, and over 80 percent of transaction are categorized as new ventures. The Novartis acquisition of Xii
- Nicox’s NCX 4251 Meets Primary Endpoint in Phase 2 Blepharitis Trial and Shows Promising Efficacy in Dry Eye Diseasehttps://modernod.com/news/nicoxs-ncx-4251-meets-primary-endpoint-in-phase-2-blepharitis-trial-and-shows-promising-efficacy-in-dry-eye-disease/2477187/Nicox SA announced that NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, has met the primary objective of its U.S. multicenter, dose escalating, first-in-human, phase 2 clinical trial (referred to as ‘Danube’) evaluating the safety and tolerability of NCX 4